Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KLKB1 | P03952 | 20/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29324563 | 0.78 | KLKB1 (0.59) | KLKB1 | |
| SCHEMBL16578697 | 0.76 | HDAC1 (0.50) | — | |
| SCHEMBL17784852 | 0.76 | KLKB1 (0.67) | KLKB1 | |
| SCHEMBL21985437 | 0.76 | KLKB1 (0.67) | KLKB1 | |
| SCHEMBL17784845 | 0.76 | KLKB1 (0.78) | KLKB1 | |
| SCHEMBL29365582 | 0.76 | KLKB1 (0.70) | KLKB1 | |
| SCHEMBL9752787 | 0.75 | POLB (0.63) | KLKB1 | |
| SCHEMBL17685619 | 0.74 | KLKB1 (0.46) | KLKB1 | |
| Bicarbonate SCHEMBL17785352 | 0.72 | KLKB1 (0.73) | KLKB1 | |
| SCHEMBL17503935 | 0.72 | GAA (0.53) | KLKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3464265-B1 | POLYMORPHS OF N-[(3-FLUORO-4-METHOXYPYRIDIN-2-YL)METHYL]-3-(METHOXYMETHYL)-1-({4-[2-OXOPYRIDIN-1-YL)METHYL]PHENYL}METHYL)PYRAZOLE-4-CARBOXAMIDE AS KALLIKREIN INHIBITORS | KALVISTA PHARMACEUTICALS LTD (GB) | 2022-07-13 | — | — | EP | claimed |
| US-20250074903-A1 | N-((HET)Arylmethyl)-Heteroaryl-Carboxamides Compounds As Kallikrein Inhibitors | DRI UK LP (KY) | 2025-03-06 | — | — | US | disclosed |
| US-20220289729-A1 | N-((HET)Arylmethyl)-Heteroaryl-Carboxamides Compounds As Kallikrein Inhibitors | KALVISTA PHARMACEUTICALS LTD (GB) | 2022-09-15 | — | — | US | disclosed |
| EP-3982961-A1 | TREATMENTS OF ANGIOEDEMA | Kalvista Pharmaceuticals Limited (GB) | 2022-04-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220289729-A1 | N-((HET)Arylmethyl)-Heteroaryl-Carboxamides Compounds As Kallikrein Inhibitors | KLKB1, BDKRB1, BDKRB2 | KLKB1 1/4885 |
| US-20250074903-A1 | N-((HET)Arylmethyl)-Heteroaryl-Carboxamides Compounds As Kallikrein Inhibitors | KLKB1, BDKRB1, BDKRB2 | KLKB1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.